Securities & Investment Fraud

The Chemours Company Securities Class Litigation

Introduction

Securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the common stock of The Chemours Company Inc. (“Chemours” or the “Company”) (NYSE: CC).  If you purchased or otherwise acquired Chemours common stock from February 16, 2017 through August 1, 2019, inclusive (the “Class Period”), you may move the court for appointment as lead plaintiff by no later than December 9, 2019.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the action.  Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market.  We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Chemours investors may choose to have Lieff Cabraser review their claim by completing the contact form below.  You can also call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358 to discuss the litigation

Background on the Chemours Securities Class Litigation

Chemours, incorporated and headquartered in Wilmington, Delaware, is a spin-off of the E.I. du Pont de Nemours and Company (“DuPont”) and produces a wide range of industrial and specialty chemicals products for various markets.  Chemours’s stock began trading as publicly traded company in 2015. The spin-off was completed pursuant to a Separation Agreement that required Chemours to indemnify DuPont for historic environmental liabilities, including those related to perfluoroalkyl and polyfluoroalkyl substances (“PFAS”), toxic chemicals that have since become the basis for environment regulatory actions, governmental prosecutions, personal injury lawsuits, and extensive remediation and other clean-up efforts.

The complaint alleges that Chemours misled investors by misrepresenting that it had correctly accounted and accumulated reserves for its environmental liabilities, that the likelihood of costs exceeding accrued amounts was “remote,” and that, in any event, added costs would not be material.  Chemours also guaranteed investors that its “policies, standards and procedures are properly designed to avoid unreasonable risk of harm to people and the environment,” and that its “handling, manufacture, use and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.” As a result of these misrepresentations, Chemours shares traded at artificially inflated prices throughout the Class Period.

On June 28, 2019, the Delaware Chancery Court unsealed a complaint that Chemours had filed against Dupont alleging that its spin-off from DuPont was part a deliberate plan by DuPont to rid itself of significant exposures incurred through decades of PFAS discharge and to unload that responsibility onto Chemours.  Following this news, the price of Chemours’s stock price fell $2.37 per share, or nearly 10%, from its closing price of $24.90 per share on June 27, 2019 to close at $22.53 per share on July 1, 2019.  On August 1, 2019, after the market closed, Chemours announced lower guidance for 2019.  On the following day, it filed its second quarter of 2019 Form 10-Q and revealed that its estimated liabilities were far greater than it had previously represented.  On this news, Chemours’s stock price declined another 19% to close at $14.69 per share on August 2, 2019 on unusually high volume eliminating over $560 million in shareholder value.

Shareholder Contact Form


First Name (required)

Last Name (required)

Email address (required)

Street Address

City

State

Zip

Telephone

How did you find our site?

Are you currently represented by an attorney?

II. TRANSACTIONS IN CHEMOURS SECURITIES

Number of shares of Chemours common stock held immediately before the start of Class Period on February 16, 2017:

From February 16, 2017 through August 1, 2019 inclusive, I made the following transactions in Chemours common stock:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

During the 90 days after August 1, 2019, I made the following transactions in Chemours common stock:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

Comments & questions:

Please sign me up for your Consumer Law newsletter. Yes


About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” In late 2016, Benchmark Litigation named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”